Qelbree, a medication for treatingacés, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2020 [1]. It is manufactured by Supernus Pharmaceuticals, Inc. [1].
How is Qelbree approved for use?
Qelbree is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years of age and older [1]. Its approval was based on clinical trials demonstrating its efficacy and safety [1].
What are the active ingredients in Qelbree?
The active ingredient in Qelbree is trazodone extended-release [1].
When does Qelbree patent expiry?
Information regarding specific patent expiry dates for Qelbree is available through resources like DrugPatentWatch.com, which tracks patent information for pharmaceutical products [2].
How does Qelbree work to treat ADHD?
The exact mechanism of action for Qelbree in treating ADHD is not fully understood [1]. However, it is believed to modulate the activity of certain neurotransmitters in the brain, including serotonin [1].
What are the common side effects of Qelbree?
Common side effects reported in clinical trials for Qelbree include somnolence, decreased appetite, fatigue, insomnia, nausea, and vomiting [1].
How does Qelbree compare to other ADHD medications?
Qelbree is a non-stimulant medication for ADHD [1]. It differs from stimulant medications, which are also commonly prescribed for ADHD [1]. Its specific comparison to other non-stimulant options, such as atomoxetine, would involve examining differences in efficacy, side effect profiles, and dosing regimens [1].